

Index

a

acetaminophen 183
 actinomycin D (AMD) 169
 acyclic L-threoninol nucleic acid (L-aTNA)
 17, 18
 adenosine triphosphate (ATP) 70, 110, 116
 adipo-8 148
 adipose tissue 147, 148
 allele mutation detection method 107
 allicin 148
 ampicillin-loaded tFNAs 44
 angiogenic peptide loaded tFNAs 15
 antibiotic resistance 45, 51, 161, 162, 168
 antibodies vs. aptamers 5
 antibody-based HCR system 107, 108
 antimicrobial peptides (AMPs) 161, 162,
 166, 169–171
 antisense oligonucleotides (ASOs) 64–65,
 70, 116, 129, 141, 149, 162, 163, 168,
 169, 184, 187
 antisense peptide nucleic acids (asPNAs)
 168, 169
 apolipoprotein B (ApoB) 142, 149
 aptamers 5, 129, 142, 150, 184, 187
 antibodies vs. 5
 AS1411-modified tFNAs 41
 based HCR system 108–109
 functionalized DNA origami delivery
 nanostructures 51
 modified DNA origami 45
 modified tetrahedral framework DNA 172
 targeted drug delivery 49
 tFNAs 126

arm-acceptor hairpins 107
 arm-donating hairpins 107
 artificial DNA nanostructures 141
 artificial nucleic acids (XNAs) 4, 17–18
 ATP-responsive HCR-based logic gate 110
 autocatalytic HCR biocircuit 103–105

b

bacterial magnetosomes 86, 87
 β -lactamases 170
 bioimaging of bone tissue regeneration
 93–94
 biological polymer DNA 37
 bionanomaterials 7, 86
 bioscaffold materials 81
 biosensing 2, 3, 7, 37, 82, 84–86, 139, 141,
 184
 bone defect 15, 81, 90, 92–94
 bone-related diseases 81–94
 bone tissue engineering 81, 93, 94
 “bottom-up” approach 1
 BSA-coated DNA origami 21

c

carbazole derivative BMEPC 44
 carbon-based nanomaterials 84, 85, 87
 caveolin-mediated endocytosis 41, 150
 cDNA 106, 188, 192
 cell targeting 47, 49, 53, 65, 66, 68, 184
 chemical antibodies 49
 chemotherapy 46, 51, 68, 115, 116, 123, 124,
 127, 129, 130

chitosan-based injectable thermosensitive hydrogel scaffold structure 93
 chondrocyte affinity peptide (CAP) exosomes 188
 circular RNA (CircRNA) 192, 194
 clearing mutant mtDNA 62–64
 clindamycin-tFNAs complex 15
 composite nanomaterials 7, 84, 87
 curcumin-loaded tFNAs 15
 cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs) 127

d

dendritic oligonucleotide-coated DNA brick nanostructures 21
 deoxyribonucleic acid (DNA) 3
 based nanocomposite hydrogels 146
 DNA-based nanomaterials 2
 history of 3–9
 hydrogel nanostructures, in antibacterial field 170
 hydrogels 162
 logic gate-based HCR 112
 nanomesh 26
 nanoribbons 170
 nanostructures 16, 162
 advantages in antibacterial field compatibility 163
 challenges and perspectives 172
 compatibility 163
 drug-loading performance 164
 editability 163
 ϵ -poly-L-lysine-DNA nanocomplex 166
 five “holes” origami framework 164
 melamine-DNA-AgNC complex 165–166
 NET-like nanogel based on 2D DNA networks 166
 stability 163
 super silver nanoclusters based 164, 165
 3D application 166, 170
 nanotechnology 161
 origami 6, 7, 22, 127–129, 161
 origami techniques 38, 144

origami technology 124
 six-helix bundle (6HB) 169
 tetrahedron 39, 144
 tiles 6
 diabetes mellitus (DM) 144–146
 diacylglycerol acyltransferase-2 (DGAT2) 142, 146, 149
 disulfide crosslinking 23
 DNA Pom-Pom nanostructure (DNA PP-N) 170
 DNA scaffold strand 38
 DNazymes 4, 5, 103
 double-crossed (DX) molecules 6
 DOX-loaded DNA origami nanosystem 52
 doxorubicin (DOX) origami delivery system 128
 dual miRNA detection system 111
 dynamic DNA nanostructures 123, 124, 130–133

e

Emapticap pegol (NOX-E36) 145
 enhanced permeability and retention (EPR) effects 128
 enzymatic ligation 22–23
 ϵ -poly-L-lysine-DNA nanocomplex 166
 erythromycin-loaded tFNA 44
 exosomes 86, 188

f

FD-RNA 68
 fluorescence-based detection 101
 2'-fluoroarabinonucleic acid (FANA) 18
 FNA-MSN nanomaterial 85
 folate 46, 47
 framework nucleic acids (FNAs) 37, 124
 advantages 37, 38
 biological properties 40–41
 classification and construction 38–40
 delivery systems in biomedical application controlled drug release 49–51
 efficient drug delivery 46
 overcoming drug resistance 49–51
 targeted drug delivery 46–49
 DNA tetrahedron 39

- fabrication and properties 39
- physical and chemical properties 40
- phytochemicals 45
- small-molecule drugs 41
 - antibiotic agents 44–45
 - antitumor agents 42–45
 - phytochemicals 45
- functional nucleic acids (FNAs) 4
 - aptamers 5
 - DNA microchips 84
 - DNA nanobots 84
 - DNA origami 6, 83
 - DNA tile 83
 - DNA tiles 6
 - DNAzymes 4
 - three-dimensional DNA self-assembly 83–84
 - triplex DNA 5–6
- g**
 - G4 17, 18
 - gamma-modified PNA(γ PNA) 17
 - glioma-specific peptide-modified tFNAs 49
 - glucagon 145, 146
 - glutaraldehyde-mediated chemical
 - crosslinking, of oligolysine-PEG5K coated DNA nanostructures 21
 - graphene-encapsulated DNA nanostructures 22
- h**
 - HApt-tFNA 126
 - hybridization chain reaction (HCR) 101
 - based assembly nanoplatfoms 113, 114
 - based *in situ* fluorescence imaging and biotherapy 102
 - based oligonucleotide drug delivery system 116
 - based tumor biotherapy 115
 - chemotherapy 115
 - photodynamic therapy 115–116
 - RNA interfering therapy 116
 - components 102
 - hairpin design principles 102
 - miRNA detection 103
 - autocatalytic HCR biocircuit 103–104
 - nonlinear HCR system 104–105
 - multiple target detection 109
 - combined HCR-based probe 109–110
 - HCR-based logic gate 110–113
 - vs. polymerase chain reaction 102
 - protein detection
 - antibody-based HCR system 107, 108
 - aptamer-based HCR system 108–109
 - single-nucleotide variants detection 105–107
 - hybrid protein-DNA hydrogel 93
- i**
 - immunotherapy 2, 53, 123, 126, 127
- l**
 - label-free HCR-based PTD method 115
 - L-DNA 17
 - ligand-modified FNAs 46
 - L12-loaded DNA hydrogel 171
 - LncRNAs 65
 - locked nucleic acid (LNA) 20, 88, 187
- m**
 - magnetic bead nanoparticles 86
 - magnetic nanomaterials 86–87
 - magnetotaxis 87
 - melamine-DNA-AgNC complex 165–166
 - melittin-loaded DNA nanostructure 124
 - mesoporous silica nanoparticles (MSN) 85
 - messenger RNA (mRNA) 64, 65, 91, 92, 102, 103, 113, 126, 142, 146, 147, 149, 184, 187, 188, 192
 - metabolic diseases 61, 139–150
 - metal-based nanomaterials 7, 84–85, 87
 - metallo- β -lactamases (M β Ls) 170
 - metal nanoclusters 85
 - methionine adenosyltransferase (MAT) 147
 - 8-methoxypsoralen (8-MOP) 23
 - microfluidic technology 110, 117
 - micropinocytosis-related proteins 41
 - microRNA-155 loaded tFNAs 15

microRNAs (miRNAs) 126
 detection
 autocatalytic HCR biocircuit 103–104
 nonlinear HCR system 104–105
 mimics 188
 mitochondrial DNA (mtDNA) 61
 clearing mutant 62–64
 inhibiting replication 64
 mitochondria targeting 66–68
 mitochondria treatment, nucleic acid-based
 delivery system in 68–71
 molecular data storage 8
 molecular nanotechnology 1
 mtRNA
 increase normal RNA 64
 non-coding RNA treating 65
 silencing abnormal RNA 64–65
 multifunctional DNA origami nanostructure
 129
 multiple target detection
 combined HCR-based probe 109–110
 HCR-based logic gate 110–113

n

naked plasmids 194
 nanotechnology 1, 3, 4, 6, 37, 52, 81–83, 88,
 103, 124, 139, 161, 164, 172
 natural nucleic acids 3
 NET-like DNA-HCl-ZnO nanogel 166
 NET-like nanogel based on 2D DNA networks
 166
 nonalcoholic fatty liver disease (NAFLD)
 140, 148, 149
 nongenetic nucleic acids 4, 141
 nonlinear HCR system 104–105, 116
 nonsteroidal anti-inflammatory drugs
 (NSAIDs) 183
 Notch receptors 147
 NOX-G15 145
 nuclease degradation 16, 20, 21, 26
 nucleic acid-based amplification reaction
 101
 nucleic acid-based antitumor treatment 101
 nucleic acid-based functional nanomaterials
 82

bionanomaterials 86
 in bone tissue repair and regeneration 89
 bioimaging 93
 bone targeting 91–92
 scaffold material 92–93
 sustained-release effect 89–91
 carbon-based 85
 characteristics 84
 composite nanomaterials 87
 magnetic nanomaterials 86–87
 metal-based 84–85
 quantum dots 86
 nucleic acid-based gene therapy 141
 nucleic acid-based nanomaterials (NAN)
 improve stability methods 15
 artificial nucleic acids 17–18
 coating with protective structures
 20–22
 construction 26
 covalent crosslinking 22–24
 improve stability 15
 nucleobase/ribose modification 19–20
 phosphate group modification 18–19
 tuning buffer conditions 23, 25
 two- or three-dimensional nanostructures
 15
 nucleic acid, description 3
 nucleic acid nanomaterials 123, 139, 141,
 150
 advances in endocrine and metabolic
 diseases 143
 application directions 82
 development of 124, 125
 for diabetes mellitus 144–146
 for nonalcoholic fatty liver disease
 148–149
 for obesity 147–148
 for osteoporosis 146–147
 properties and applications
 DNA origami 127–129
 dynamic DNA nanostructure 130–133
 tFNAs 125–127
 nucleic acid nanoparticles, as carriers for OA
 therapy 194

- nucleic acid nanotechnology 82, 83, 124, 139, 141
- nucleic acid sequences 6, 15, 62
- o**
- obesity 139, 140, 147–149, 183
- oral hypoglycemic agents 144
- osteoarthritis (OA) 181
- nucleic acid nanomaterials-based therapy 184
 - pathology of 181–182
 - risk factors 183
 - therapy challenges 183
 - vector-dependent 188–194
 - vector-independent 184–188
- osteoporosis 81, 91, 93, 146–147
- overcoming drug resistance 43, 51, 52
- p**
- PEG-DNA structure 20
- PEG-protamine-tetrahedral framework DNA (PPT) complex 172
- penicillin-binding proteins (PBPs) 168
- peptide-decorated FNAs 49
- peptide nucleic acids (PNA) 17, 64, 69, 88
- pharmacological therapy 140
- photochemical crosslinking 23
- photodynamic therapy (PDT) 43, 44, 68, 70, 102, 115–116, 123, 127
- photothermal therapy (PTT) 7, 43, 46, 89, 130
- pH-sensitive FNA design 51
- phytochemicals 45, 49, 148
- plasmids 93, 184, 192, 194
- point of care (POC) detection 102
- polymerase chain reaction (PCR) 102, 142
- polymeric DNA-based nanomaterials 2
- proinflammatory chemokine C-C motif-ligand 2 145
- protein-coated DNA origami 20
- protein detection
- antibody-based HCR system 107, 108
 - aptamer-based HCR system 108–109
- protein kinase A (PKA) phosphorylates sub-peptide 113
- protein tyrosine phosphatase-1B (PTP1B) 146
- proteomic identification method 41
- q**
- quantitative polymerase chain reaction (qPCR) 168
- quantum dots 84, 86, 87, 93, 94, 108
- r**
- recombinase polymerase amplification (RPA) 106, 107
- resveratrol 45
- ribonucleic acid (RNA) 3
- interfering therapy 116
- s**
- scaffold material, for bone regeneration 92–93
- SELEX *in vitro* screening technique 4
- SELEX system 148
- self-assembled 3D FNA nanostructures 7
- self-assembled DNA nanostructure 38
- self-assembled DNA nanotechnology 88
- self-assembled FNAs 40
- self-assembled nucleic acid nanostructures 88
- serine/threonine protein kinase (STK)25 149
- short tube DNA origami (STDO) 21
- single-nucleotide variants (SNV) detection 105–107
- siRNA-templated 3D spherical FNAs 50
- small interfering RNAs (siRNAs) 126
- nucleic acid drugs 141
 - vector-dependent nucleic acid nanomaterials for OA therapy 188, 192
- small-molecule drugs 41
- antibiotic agents 44–45
 - antitumor agents 42–45
 - chemotherapeutic drugs 42–43
 - phototherapeutic agents 43–44
 - phytochemicals 45
- sodium glucose cotransporter-2 (SGLT2) 146

spherical nucleic acids (SNAs) 91, 148, 149
stimuli-sensitive FNAs 51
sub-peptide modified silica nanoparticles 113
super silver nanoclusters based on branched DNA 164–165
systematic evolution of ligands by the exponential enrichment (SELEX) process 49
systemic drug delivery, of gene-related therapeutics 142

t

tensegrity triangle 124
tetrahedral DNA-based nanomaterials (TDNs) 2, 9
tetrahedral framework DNA 166
 nucleic acid antibiotics delivery 168–169
 polypeptide antibiotics delivery 169
 traditional antibiotics delivery 168
tetrahedral framework nucleic acids (tFNAs) 15, 124, 144, 145
 ampicillin-loaded 44
 angiogenic peptide loaded 15
 aptamer AS1411-modified 41
 aptamers 126
 clindamycin-tFNAs complex 15
 curcumin-loaded 15
 erythromycin-loaded 44
 glioma-specific peptide-modified 49
 HApt 126
 microRNA-155 loaded 15
 nanostructures 88
 nucleic acid nanomaterials 125–127

tetrahedron-loaded hairpins 113
TE20-type kinase MST3 149
3D DNA-based nanomaterials 8, 9
toehold-mediated strand displacement (TMSD) 103
“top-down” approach 1
traditional bone tissue regeneration treatment methods 81
transferrin 129
triplex DNA 5–6
triplex-forming oligonucleotides (TFOs) 5
tumor cell membrane antigen detection 107

v

vector-dependent nucleic acid nanomaterials, for OA therapy 189–191
 cDNA 192
 CircRNA 192, 194
 miRNA mimics 188
 mRNA 192
 small interfering RNA 188, 192
vector-independent nucleic acid nanomaterials, for OA therapy 184
 antisense oligonucleotides 187
 aptamers 187–188
 tFNA
 biodistribution of 185
 therapeutic effect of 184–185, 187
VicK protein-related gene 168
vildagliptin 145
vitamin B12 (VB12) 46

w

wild-type mtRNA (WT-mRNA) 64

